About Zantac Lawsuit
Zantac (ranitidine) was one of the most widely prescribed medications in the United States, used by millions to treat heartburn, acid reflux, and ulcers. In 2019, the FDA discovered that ranitidine tablets and liquid formulations contained unacceptable levels of NDMA (N-nitrosodimethylamine), a probable human carcinogen. Despite knowing about the contamination, manufacturers did not immediately warn consumers or remove the product from shelves.
NDMA is a chemical compound with well-documented carcinogenic properties. Long-term ingestion of ranitidine products contaminated with NDMA significantly increases cancer risk, particularly stomach, colon, bladder, and kidney cancers. Patients who took Zantac as prescribed for years or decades faced cumulative NDMA exposure without knowing about the contamination.
In September 2020, the FDA requested removal of ranitidine from the market, but by then millions had already been exposed. GSK and other manufacturers reached settlement agreements, though litigation continues. If you took Zantac or ranitidine products and later developed cancer, you may be eligible for substantial compensation.